• LAST PRICE
    1.1500
  • TODAY'S CHANGE (%)
    Trending Up0.0400 (3.6036%)
  • Bid / Lots
    1.1000/ 13
  • Ask / Lots
    1.1800/ 8
  • Open / Previous Close
    1.1500 / 1.1100
  • Day Range
    Low 1.0800
    High 1.1596
  • 52 Week Range
    Low 0.9900
    High 2.5362
  • Volume
    418,135
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.11
TimeVolumeIMAB
09:32 ET41961.1338
09:36 ET20751.1511
09:38 ET196411.13
09:39 ET23001.11
09:41 ET14591.11
09:43 ET18061.1101
09:45 ET25001.14
09:48 ET1001.14
09:50 ET54521.125
09:52 ET43901.12
09:54 ET29291.105
09:56 ET53001.11
09:59 ET1281.115
10:01 ET13001.1
10:03 ET44251.12
10:08 ET1001.12
10:10 ET1001.12
10:12 ET284511.09
10:14 ET14411.09
10:15 ET58651.08
10:17 ET23691.0802
10:19 ET104701.0985
10:21 ET20921.105
10:24 ET241681.1
10:26 ET16001.11
10:28 ET16001.1
10:32 ET26501.1096
10:33 ET3641.1085
10:37 ET2921.11
10:39 ET1001.11
10:42 ET37971.12
10:44 ET1001.12
10:48 ET1001.115
10:50 ET20511.1101
10:51 ET25001.11
10:53 ET15001.1196
10:55 ET1001.115
10:57 ET1001.11
11:00 ET61701.11
11:02 ET28911.1
11:06 ET1761.105
11:08 ET2551.108
11:09 ET1001.11
11:13 ET1011.115
11:18 ET1001.12
11:22 ET3001.12
11:26 ET113351.1191
11:27 ET16761.1106
11:31 ET106011.12
11:40 ET24001.11
11:42 ET8001.11
11:45 ET15001.1
11:47 ET1001.11
11:56 ET10001.11
12:00 ET2001.12
12:02 ET32711.11
12:07 ET32001.1
12:20 ET3341.1004
12:23 ET1001.11
12:27 ET7001.11
12:30 ET1001.105
12:32 ET4501.105
12:34 ET59001.109999
12:38 ET21001.11
12:39 ET45501.1094
12:43 ET1001.11
12:45 ET7871.105
12:48 ET39711.1
12:50 ET2001.11
12:57 ET10001.1038
01:01 ET64001.105
01:08 ET100001.11
01:10 ET21021.105
01:12 ET2001.11
01:21 ET1001.11
01:24 ET106001.105
01:26 ET5001.105
01:28 ET39511.1004
01:30 ET1001.11
01:32 ET144001.11
01:33 ET39901.11
01:35 ET12341.11
01:37 ET56501.11
01:44 ET12601.1108
01:46 ET3001.12
01:48 ET3291.1104
01:50 ET1001.12
01:53 ET15001.12
01:57 ET1001.12
02:00 ET11511.11
02:02 ET14021.1127
02:04 ET39521.1101
02:08 ET1001.115
02:18 ET1001.12
02:20 ET16201.115
02:22 ET1001.12
02:24 ET200001.11
02:26 ET54721.11
02:29 ET1001.11
02:31 ET51921.11
02:44 ET35981.11
02:49 ET1001.115
02:54 ET3001.12
02:56 ET1001.11
03:00 ET19501.11
03:02 ET1001.12
03:03 ET31001.12
03:05 ET2001.12
03:07 ET1001.12
03:09 ET4221.12
03:12 ET1001.12
03:14 ET15001.115
03:16 ET1001.12
03:18 ET2001.12
03:20 ET14071.12
03:21 ET23001.12
03:23 ET26931.12
03:25 ET23551.12
03:27 ET11951.12
03:30 ET1001.12
03:32 ET1001.12
03:34 ET4501.11
03:36 ET46051.12
03:38 ET97981.13
03:39 ET1001.12
03:41 ET3001.125
03:43 ET5001.13
03:45 ET6131.13
03:48 ET1001.13
03:50 ET339901.145
03:52 ET7001.15
03:54 ET15001.1401
03:56 ET28031.14
03:57 ET67591.15
03:59 ET47281.15
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMAB
I-Mab
85.7M
0.0x
---
United StatesVRCA
Verrica Pharmaceuticals Inc
84.1M
-0.9x
---
United StatesZHYBF
Zhong Yuan Bio-Technology Holdings Ltd
88.2M
391.4x
---
United StatesCLRB
Cellectar Biosciences Inc
76.4M
-0.6x
---
United StatesEDTXF
Spectral Medical Inc
138.8M
-9.2x
---
United StatesHCIL
Hongchang International Co Ltd
129.7M
-450.0x
---
As of 2024-09-29

Company Information

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Contact Information

Headquarters
Suite 400, 2440 Research BlvdROCKVILLE, MD, United States 20850
Phone
301-670-2800
Fax
---

Executives

Chairman of the Board
Wei Fu
Interim Chief Executive Officer, Director
Xi-Yong Fu
Chief Financial Officer
Joseph Skelton
Chief Medical Officer
Phillip Dennis
Director
Shuai Chen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$85.7M
Revenue (TTM)
---
Shares Outstanding
80.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.07
EPS
---
Book Value
$3.00
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.